Literature DB >> 1239961

Accuracy of 99mTC-diphosphonate bone scans and roentgenograms in the detection of prostate, breast and lung carcinoma metastases.

J D Osmond, H P Pendergrass, M S Potsaid.   

Abstract

A technetium 99m diphosphonate scan is a sensitive detector of bony metastases of breast, prostate, and lung cancer. For these particular neoplasms, a negative bone scan in an asymptomatic patient is adequate evidence for absence of bony metastases and a correlative roentgenographic examination may not be necessary. Positive studies demonstrating multiple characteristic discrete areas of increased activity should be considered strong evidence for metastases. Single equivocal lesions require roentgenographic and occasionally biopsy correlation. If roentgenography fails to reveal the source of increased uptake, (e.g., degenerative disease) the scan lesion should remain suspicious for metastases.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1239961     DOI: 10.2214/ajr.125.4.972

Source DB:  PubMed          Journal:  Am J Roentgenol Radium Ther Nucl Med        ISSN: 0002-9580


  20 in total

1.  Super bone scan: bone metastases of prostate cancer.

Authors:  Kiyoshi Shikino; Masatomi Ikusaka; Yusuke Hirota; Eri Sato
Journal:  BMJ Case Rep       Date:  2014-09-16

2.  Bone scintigraphy, radiographic survey and prostatic acid phosphatase in patients with prostatic carcinoma. A comparison of sensitivity.

Authors:  O Reikerås; J Due; J A Sundsfjord
Journal:  Int Urol Nephrol       Date:  1988       Impact factor: 2.370

3.  Serial radionuclide imaging during treatment of patients with diffuse bone metastases from carcinoma of the prostate.

Authors:  A C Perkins; J G Hardy; M L Wastie; K M Clifford
Journal:  Eur J Nucl Med       Date:  1982

4.  CT of the spine.

Authors:  G Krol; R Khomeini; M F Deck
Journal:  Neuroradiology       Date:  1978       Impact factor: 2.804

5.  Comparison of distribution characteristics of metastatic bone lesions between breast and prostate carcinomas.

Authors:  Chang-Yin Wang; Guang-Yao Wu; Mei-Juan Shen; Kun-Wei Cui; Ying Shen
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

6.  Accumulation of 99mTc-HM-PAO in photon deficient areas in bone scan of bone metastasis from hepatocellular carcinoma.

Authors:  N Otsuka; M Fukunaga; K Morita; S Ono; K Nagai; T Tomomitsu; S Yanagimoto; H Mimura; S Yamamoto; Y Hirano
Journal:  Ann Nucl Med       Date:  1992-11       Impact factor: 2.668

7.  Repeated quantitative bone scintigraphy in patients with prostatic carcinoma treated with orchiectomy.

Authors:  G M Sundkvist; L Ahlgren; B Lilja; S Mattsson; P A Abrahamsson; L B Wadström
Journal:  Eur J Nucl Med       Date:  1988

8.  Bone marrow scintigraphy in the diagnosis of bone metastasis in prostate cancer.

Authors:  H Fuse; O Nagakawa; H Seto; T Katayama
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

9.  Differentiation of malignant and degenerative bone lesions using dexamethasone interventional 3- and 24-hour bone scintigraphy.

Authors:  A Bhatnagar; A Mondal; R Kashyap; R K Sharma; R Sharma; S K Chakravarty; V Bihari; K Sawroop; M K Chopra; N L Soni
Journal:  Eur J Nucl Med       Date:  1994-07

10.  The usefulness of bone-marrow scintigraphy in the detection of bone metastasis from prostatic cancer.

Authors:  N Otsuka; M Fukunaga; T Sone; M Yoneda; N Saito; H Tanaka; T Tomomitsu; S Yanagimoto; A Muranaka; R Morita
Journal:  Eur J Nucl Med       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.